Watchlist Price Alert

Aligos Therapeutics Inc. (ALGS)

NASDAQ: ALGS · Real-Time Price · USD

4.44

-0.14 (-3.06%)

At close: May 07, 2025, 3:59 PM

4.65

4.73%

After-hours: May 07, 2025, 05:56 PM EDT

-3.06% (1D)

Bid	4.22
Market Cap	27.24M
Revenue (ttm)	3.94M
Net Income (ttm)	-131.21M
EPS (ttm)	-20.94
PE Ratio (ttm)	-0.21
Forward PE	-0.38
Analyst	Buy

Ask	4.9
Volume	70,671
Avg. Volume (20D)	184,340
Open	4.63
Previous Close	4.58
Day's Range	4.36 - 4.59
52-Week Range	3.76 - 46.80
Beta	2.76

About ALGS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALGS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALGS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Aligos Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $311K misses estimates by $189K, with -68.46% YoY decline.

EPS of -2.11 exceeds estimates by 1.04, with 62.19% YoY growth.

Why Price Moved

1 month ago

-19.55%

Aligos Therapeutics shares are trading lower after... Unlock content with Pro Subscription

2 months ago

-19.25%

Aligos Therapeutics shares are trading lower after the company announced a $105 million private placement financing round.

News

1 day ago · zacks.com

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.

1 month ago · businesswire.com

LIVMARLI Now Approved in Japan for ALGS and PFIC

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.

1 month ago · zacks.com

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.